Floatz logo

Tildacerfont

CAH - Congenital Adrenal Hyperplasia

Spruce BiosciencesSmall moleculePhase 2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the CAH - Congenital Adrenal Hyperplasia cohort.

Asset / SponsorPhaseRating
Atumelnant
Crinetics Pharmaceuticals Inc.
Phase 3BB
Crinecerfont
Neurocrine Biosciences
Phase 2B

Same molecule, other indications

Tildacerfont is also rated in:

congenital adrenal hyperplasiaDormant
CC
Indicative ·
41 / 100
View asset →
classic congenital adrenal hyperplasia due to 21-hydroxylase deficiencyDormant
C
Indicative ·
38 / 100
View asset →
polycystic ovary syndromeDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →